$837 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 17 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ODT | ODONATE THERAPEUTICS INC | $456,742,000 | +24.7% | 14,075,269 | 0.0% | 54.57% | -12.9% | |
RCKT | ROCKET PHARMACEUTICALS INC | $67,494,000 | +95.4% | 2,965,485 | 0.0% | 8.06% | +36.4% | |
LJPC | LA JOLLA PHARMACEUTICAL CO | $19,410,000 | -55.3% | 4,938,893 | 0.0% | 2.32% | -68.8% | |
PRTA | PROTHENA CORP PLC | $6,709,000 | +101.9% | 423,823 | 0.0% | 0.80% | +40.9% | |
PBYI | PUMA BIOTECHNOLOGY INC | $3,057,000 | -18.7% | 349,400 | 0.0% | 0.36% | -43.2% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
4 | 2024-02-14 |
4 | 2024-02-02 |
4 | 2023-12-18 |
13F-HR | 2023-11-14 |
4 | 2023-10-13 |
13F-HR | 2023-08-14 |
3 | 2023-06-01 |
4 | 2023-06-01 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.